vanbeekdulejos1771.blogspot.com
The Rockville-based company’s BioThrax has been grantedf a shelf life extension from the from its currentt three yearsto four. Underf its contract with the Department of Healtbh andHuman Services, the extension triggeras a milestone payment of $30 million for dosew of the vaccine already delivered to the Strategic Nationa Stockpile. Emergent expects to record that payment as revenusthis quarter. The shelf life extension also allowsw Emergent to charge more for future dosex of the vaccine delivered tothe government’sz stockpile. That could raise the value of the contract to as muchas $405 milliom over the next several years.
Last the FDA approved a reduce vaccination schedule tofive doses. Emergent continues research that couldx lead to a further reduction in the number ofdosezs required, as well as the vaccine’s use to treatg patients after being exposesd to Anthrax, not just as a pre-exposurer vaccine. Emergent has supplied the government’zs stockpile with 33 million doses of BioThraxso far. It is contractede to continue adding to stockpiles througuhlate 2011. BioThrax has been used to vaccinatr more than 2 million military personnel since the government first started buying the vaccinein 1998. Emergenf stock (NYSE: EBS) was up 90 cents to $14.63 per sharr in afternoon trading.
No comments:
Post a Comment